Cited 68 times in
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2021-09-29T01:53:58Z | - |
dc.date.available | 2021-09-29T01:53:58Z | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 1479-6694 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184604 | - |
dc.description.abstract | Standard-of-care, first-line therapy for patients with advanced HER2+ gastric/gastroesophageal junction adenocarcinoma is chemotherapy plus trastuzumab, a monoclonal antibody (mAb) targeting HER2. Margetuximab is an Fc-optimized mAb that binds HER2. Retifanlimab, a humanized IgG4 mAb, binds to PD-1 and blocks its interaction with PD-L1/2. Tebotelimab, an IgG4κ bispecific DART® molecule, binds PD-1 and lymphocyte activation gene 3 concomitantly, disrupting these nonredundant inhibitory pathways to further restore exhausted T-cell function. Here, we describe the design and rationale of the randomized, open-label, Phase II/III MAHOGANY trial evaluating margetuximab plus retifanlimab with/without chemotherapy and margetuximab plus tebotelimab with chemotherapy in first-line unresectable metastatic/locally advanced gastroesophageal junction adenocarcinoma. Primary end points include objective response rate, overall survival and safety/tolerability. Clinical trial registration: NCT04082364 (ClinicalTrials.gov). | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Future Medicine Ltd. | - |
dc.relation.isPartOf | FUTURE ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Daniel Vt Catenacci | - |
dc.contributor.googleauthor | Minori Rosales | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Harry H Yoon | - |
dc.contributor.googleauthor | Lin Shen | - |
dc.contributor.googleauthor | Markus Moehler | - |
dc.contributor.googleauthor | Yoon-Koo Kang | - |
dc.identifier.doi | 10.2217/fon-2020-1007 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J00914 | - |
dc.identifier.eissn | 1744-8301 | - |
dc.identifier.pmid | 33263418 | - |
dc.subject.keyword | HER2 | - |
dc.subject.keyword | I-O combination | - |
dc.subject.keyword | LAG-3 | - |
dc.subject.keyword | PD-1 | - |
dc.subject.keyword | checkpoint inhibitor | - |
dc.subject.keyword | first-line therapy | - |
dc.subject.keyword | gastric cancer | - |
dc.subject.keyword | gastroesophageal adenocarcinoma | - |
dc.subject.keyword | gastroesophageal junction cancer | - |
dc.subject.keyword | immuno-oncology | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.citation.volume | 17 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1155 | - |
dc.citation.endPage | 1164 | - |
dc.identifier.bibliographicCitation | FUTURE ONCOLOGY, Vol.17(10) : 1155-1164, 2021-04 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.